Gilead Sciences (NASDAQ:GILD) Stock Rating Upgraded by StockNews.com

Gilead Sciences (NASDAQ:GILD) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Other equities research analysts also recently issued reports about the stock. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research note on Wednesday, April 24th. Cantor Fitzgerald reduced their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. TD Cowen dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday. Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Finally, Morgan Stanley dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and an average price target of $83.87.

Gilead Sciences Trading Up 0.2 %

GILD stock opened at $65.42 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The company’s 50-day simple moving average is $71.28 and its 200 day simple moving average is $76.25. Gilead Sciences has a 52 week low of $64.63 and a 52 week high of $87.86. The company has a market capitalization of $81.45 billion, a PE ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the company posted $1.37 earnings per share. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences will post 3.82 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GILD. Capital World Investors boosted its position in shares of Gilead Sciences by 2.0% during the 4th quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock worth $6,753,350,000 after purchasing an additional 1,642,736 shares in the last quarter. Capital Research Global Investors lifted its stake in shares of Gilead Sciences by 3.0% in the fourth quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after buying an additional 1,743,418 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after buying an additional 2,350,550 shares during the last quarter. Morgan Stanley increased its position in shares of Gilead Sciences by 0.9% during the third quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after acquiring an additional 158,794 shares in the last quarter. Finally, Norges Bank bought a new position in Gilead Sciences in the 4th quarter valued at about $1,301,624,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.